Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 1 Main data from the study
Control group | CCEF group | p value | |
|---|---|---|---|
Patients, n (VFFs) | 33 (VFFs = 34) | 33 (VFFs = 35) | – |
Gender | |||
Male, n (%) | 4 (12.12%) | 5 (15.15%) | 0.65 |
Age | |||
Mean ± SD | 72.88 ± 6.09 | 73.6 ± 7.82 | 0.768 |
Range | 65–84 | 64–83 | – |
BMI (kg/m2) | |||
Mean ± SD | 26.055 ± 3.9 | 26.735 ± 4.35 | 0.722 |
Smoking status | |||
N of smokers (%) | 10 (30.3%) | 10 (30.3%) | – |
Vertebral fracture type (OF classification) | |||
OF 1, n (%) | 1 (2.94%) | 2 (5.7%) | 0.03* |
OF 2, n (%) | 33 (97.06%) | 33 (94.3%) | 0.07 |
Vertebral fracture site | |||
T10, n (%) | 3 (8.82%) | 3 (8.57%) | 0.83 |
T11, n (%) | 4 (11.76%) | 3 (8.57%) | 0.83 |
T12, n (%) | 9 (26.47%) | 10 (28.6%) | 0.21 |
L1, n (%) | 10 (29.42%) | 11 (31.4%) | 0.11 |
L2, n (%) | 5 (14.71%) | 5 (14.29%) | 0.88 |
L3, n (%) | 3 (8.82%) | 3 (8.57%) | 0.83 |
Adverse reactions to CCEF | |||
N (%) | 0 | N/A | – |
Patient compliance | |||
Adherence (%) | 94% | N/A | – |
Oedema resolution per hour of CCEF therapy (mm2/h) | |||
ΔE (mean ± SD) | 0.95 ± 0.47 | N/A | – |